Neil Cashman

Dr Neil Cashman is chief scientific officer and co-founder of Toronto-based ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), which is advancing an investigational antibody, PMN 310, that binds to neurotoxic Aβ oligomers for disease modifying treatment for Alzheimer’s Disease. Dr. Cashman is a global leader in neurodegenerative diseases and one of the most cited researchers in protein misfolding diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s diseases.

Articles: Neil Cashman

Alzheimer’s Immunotherapies: Are We There Yet?

Canada / Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific stagnation. Are we there yet with Alzheimer’s immunotherapies? No. But we have a map, and it’s a good one. In late September 2022,…

Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

USA / In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory Committee’s meeting on November 6 2020, what it means for that Aducanumab, and the impact on next-generation AD treatments. November 6 could prove to be a milestone day for the…

Aducanumab: On the Regulatory Home Stretch in the USA

Opinion / In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr Neil Cashman highlights what the next steps in the process will be, why US FDA approval for the drug will pave the way for researchers working on second-generation AD medicines, and how the future for…

Worried About Biogen’s Aducanumab? Don’t Be

Opinion / Dr Neil Cashman examines the recent news around Biogen’s Alzheimer’s treatment aducanumab, assuages some investor fears, and underlines the treatment’s solid fundamentals and potential. On April 2020, Biogen initiated regulatory review for aducanumab, its investigational therapy for Alzheimer’s disease. Investors reacted negatively, and this reverberated throughout the Alzheimer’s research and patient communities, causing—in my…

Alzheimer’s Disease Treatment: Canadian-Led Innovation Post-Aducanumab

Canada / Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading role in the development of the next generation of AD therapies. We’re at the advent of a potential landmark year in the search for…